N/A N=204 Safety & Prevention Outcomes Study
Drug Overdose · Opioid-Related Disorders
Primary: Overdose Risk Behavior — -1.54; -0.51 Scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,337 Special Investigation For Long-Term Use Of Sildenafil (Regulatory Post Marketing Commitment Plan)
Pulmonary Hypertension
Primary: Number of Participants With Treatment-Related Adverse Events — 448; 101 Participants
N/A N=1,164 Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)
Chronic Heart Failure
Primary: Percentage of Participants With Adverse Drug Reactions in Chronic Heart Failure Participants With Moderate Renal Impairment — 9.49; 1.58 Percentage of Participants
N/A N=2,029 Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)
Non-small Cell Lung Cancer
Primary: Number of Participants With Adverse Drug Reactions — 1858; 518 Participants
N/A N=3,430 Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice
Osteoporosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 209; 17 Participants
N/A N=396 Achieving Medication Safety During Acute Kidney Injury
Kidney Failure, Acute
Primary: Adverse Drug Events or Potential Adverse Drug Events — 99; 104 Patient-Medication Pairs
Phase 2 N=229 An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
Type 2 Diabetes Mellitus
Primary: Annual Rate of Change in FEV1 From Baseline to End of Study — -0.048 Liters per year
N/A N=136 mHealth Medication Safety Intervention
Medication Compliance
Primary: Number of Medication Errors — 9; 20 number of medication errors
N/A N=3,939 Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
N/A N=472 Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Treatment-Related Adverse Events — 450 Participants
N/A N=68 Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)
CCR5-tropic HIV-1 Infection
Primary: Percentage of Participants With Adverse Drug Reactions (ADRs) — 23.53 percentage of participants
N/A N=7,740 Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
N/A N=451 Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
N/A N=8 Safety and Efficacy of Trastuzumab BS
Gastric Cancer
Primary: The Incidence of Adverse Drug Reactions (ADRs) — 4; 0 Participants
N/A N=3 Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
HIV-1 Infection
Primary: Number of Participants Who Reported Unlisted Adverse Drug Reaction. — 0 participants
N/A N=149 Medication Education for Dosing Safety
Pain · Fever
Primary: Number of Participants Reporting Safe Dosing at 48-72 Hours — 28; 25 Participants
N/A N=502 Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
Bacterial Infections
Primary: Number of Participants With an Investigator's Assessment of Clinical Outcome (Effective (Cured)/ Not Effective (Not Cured)) at End of the Study. — 438; 19 participants
Phase 2 N=237 PT003 MDI Cardiovascular Safety Study
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in 24-Hour Mean Heart Rate Post-dose — -0.19; -1.84; 0.40; -0.09 bpm
N/A N=2,272 Drug Use Investigation of Jzoloft.
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
Phase 3 N=259 Antibiotic Safety (SCAMP)
Complicated Intra Abdominal Infections
Primary: Death — 5; 5; 7; 1 Participants
N/A N=135 Absorb GT1 Japan PMS
Ischemic Heart Disease · Angina Pectoris · Coronary Artery Disease
Primary: Number of Participants With Acute Scaffold Thrombosis (ST) — 0; 0; 0 participants
N/A N=11,157 Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Overactive Bladder
Primary: Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). — 984 participants
N/A N=1,005 Testing a Medication Risk Communication and Surveillance Strategy: The EMC2 Trial
High-risk Medications
Primary: Medication Knowledge (0-100) — 71.2; 71.9; 73.2; 74.9 score on a scale
N/A N=206 Safety Follow-Up to HP 802-247-09-015
Venous Leg Ulcer · Venous Stasis Ulcer
Primary: The Number of Participants With Closed Target Ulcers at Each Visit — 27; 21; 25; 23 participants
Phase 1 N=72 Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 5.6 Percentage of participants
N/A N=682 Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Glioblastoma · Glioma · Astrocytoma
Primary: Number of Participants Experiencing Adverse Events (AEs) — 324 participants
Phase 2 N=59 Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
Adrenocortical Adenoma · Endometrial Stromal Sarcomas
Primary: Incidence of Adrenal Cortical Adenomas — 3 Particpants
N/A N=2,017 a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients
Parkinson Disease
Primary: Incidence of AE/SAE — 5.16 Percentage of participants
N/A N=2,860 Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)
Arthritis · Rheumatoid · High Dose
Primary: Number of Participants With Treatment-Related Adverse Events — 608 Participants
N/A N=374 Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).
Urinary Bladder, Overactive
Primary: Adverse Drug Reaction Not Expected From the Japanese Package Insert. Number of Unlisted Treatment Related Adverse Events (TRAEs). — 1; 1; 1 participants